# Full Article: Reconstructing Menopausal Hormone Therapy Guidelines

## üìÑ Documents

- **[PDF Version](mht-guideline-reconstruction.pdf)** - Formatted document (recommended for printing, formal citation, and comprehensive reading)
- **Markdown Version** - Coming soon (web-readable format)

---

## üìã Abstract

On November 10, 2025, the FDA formally reversed twenty-three years of restrictive guidance on menopausal hormone therapy (MHT), acknowledging that the Women's Health Initiative evidence does not appropriately apply to modern formulations. This regulatory reversal exposes persistent institutional inertia: despite acknowledgment, no guideline review or reassessment has been announced by ACOG or NAMS.

Comprehensive guideline reconstruction is therefore not optional refinement‚Äîit is institutional necessity. This analysis addresses three interconnected dimensions:

1. **Conceptual Reality**: Menopause reclassification from genitourinary/reproductive to endocrine disease‚Äîspecifically, age-related endocrine insufficiency
2. **Pharmacological Reality**: All current restrictive MHT guidance rests on the Women's Health Initiative (WHI), which tested formulations fundamentally different from modern bioidentical MHT
3. **Institutional Reality**: The perpetuation of restrictive MHT guidance operates through six interdependent institutional mechanisms documented in the Evidence-Selective Medicine (ESM) framework

---

## üìñ Document Structure

### Part I: The Conceptual Crisis
Menopause as arbitrary medical classification - examining the endocrine principles and ICD-11 classification problems

### Part II: The Formulation Category Error
WHI as non-evidence for modern MHT - pharmacological mismatch and contemporary registry evidence

### Part III: Institutional Architecture
The Six-Level Model of Evidence-Selective Medicine explaining guideline persistence mechanisms

### Part IV: Formulation-Specific Evidence
Breast cancer survivors and modern bioidentical regimens - refuting prohibition assumptions

### Part V: Ecological Health Promotion
Disease prevention model reframing from symptom minimization to prevention

### Part VI: Disease Prevention as Primary Goal
Expanded indications and evidence-based benefits (cardiovascular, bone, metabolic, cognitive)

### Part VII: Legal and Ethical Reconstruction
From custom-based to evidence-based standards under 2024 Restatement (Third) of Torts

### Part VIII: Clinical Equipoise and Future Research
Disappearing equipoise and shift to dose-optimization trial designs

### Part IX: Systemic-Level Reconstruction
Policy, regulatory, and educational change requirements

### Part X: Addressing Counterarguments
Common objections and evidence-based responses, limitations and caveats

---

## üìä Key Evidence

### Modern MHT Safety Profile

| Outcome | Effect | Evidence Source |
|---------|--------|-----------------|
| VTE (transdermal E2) | No increase | KEEPS (0 events), multiple registries |
| Breast cancer (E2+P4) | No increase | E3N-EPIC (RR 0.9), Cold et al. (HR 1.05, NS) |
| CV mortality | 30-50% reduction | DOPS (HR 0.48), meta-analyses |
| Hip fracture | 25% reduction | WHI, registries |
| Type 2 diabetes | 20-30% reduction | Long-term follow-up studies |
| Alzheimer's risk | 35% reduction (early) | Multiple cohorts |

### WHI vs. Modern Formulations

| Parameter | WHI (CEE/MPA) | Modern (E2/P4) |
|-----------|---------------|----------------|
| Estrogen | Conjugated equine | Bioidentical 17Œ≤-estradiol |
| Route | Oral | Transdermal |
| Hepatic metabolism | Extensive | Bypassed |
| VTE risk | Increased (HR 1.8) | No increase |
| Breast effects | Proliferative (MPA) | Neutral/protective (P4) |

---

## üéØ Citation

**Academic citation:**
```
Catherino, D. (2025). Reconstructing Menopausal Hormone Therapy Guidelines: 
From Palliative Symptom Management to Age-Related Endocrine Insufficiency 
Disease Prevention. GitHub repository. 
https://github.com/YOUR-USERNAME/mht-guideline-reconstruction
DOI: YOUR-ZENODO-DOI
```

**Legal citation:**
```
Dolores Catherino, Reconstructing Menopausal Hormone Therapy Guidelines: 
From Palliative Symptom Management to Age-Related Endocrine Insufficiency 
Disease Prevention (2025), available at 
https://github.com/YOUR-USERNAME/mht-guideline-reconstruction
```

---

## üìö Related Resources

- **[Evidence Synthesis](../evidence-synthesis/)** - Detailed data tables and trial comparisons
- **[ESM Framework](https://github.com/YOUR-USERNAME/evidence-selective-medicine)** - Theoretical framework explaining institutional mechanisms
- **[Patient Resources](../patient-resources/)** - Accessible summaries and informed consent guidance
- **[Clinician Resources](../clinician-resources/)** - Legal defensibility and prescribing guidance
- **[Policy Analysis](../policy-analysis/)** - ICD-11 reclassification and regulatory strategy

---

## üí° For Different Audiences

**Researchers**: Read sequentially for complete argumentation and comprehensive evidence synthesis

**Clinicians**: Focus on Part II (formulation evidence), Part VI (disease prevention), and Part VII (legal framework)

**Attorneys**: Focus on Part VII (legal reconstruction) and Part III (institutional mechanisms documenting organizational knowledge)

**Policy Makers**: Focus on Part I (conceptual reclassification), Part IX (systemic reconstruction), and Part VI (prevention framework)

**Patients/Advocates**: Start with Executive Summary, then Part X (counterarguments) for accessible overview

---

## üîÑ Document History

- **December 2, 2025**: Initial publication
- **[Updates will be tracked here]**

---

## üìû Contact

For academic inquiries, media requests, or collaboration:
[Add your contact information]

For community discussion:
[GitHub Discussions](../../discussions)

---

## ‚öñÔ∏è License

This work is licensed under Creative Commons Attribution 4.0 International License (CC BY 4.0)

You are free to share and adapt with attribution.

---

[‚Üê Back to main repository](../)
